Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-cash Items (2023 - 2025)

CG Oncology (CGON) has disclosed Non-cash Items for 3 consecutive years, with $198.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 83.57% year-over-year to $198.5 million, compared with a TTM value of $198.5 million through Dec 2025, up 83.57%, and an annual FY2025 reading of $198.5 million, up 83.57% over the prior year.
  • Non-cash Items was $198.5 million for Q4 2025 at CG Oncology, up from $190.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $231.2 million in Q1 2024 and bottomed at $40.3 million in Q4 2023.
  • Average Non-cash Items over 3 years is $141.5 million, with a median of $153.0 million recorded in 2024.
  • The sharpest move saw Non-cash Items surged 168.44% in 2024, then tumbled 62.23% in 2025.
  • Year by year, Non-cash Items stood at $40.3 million in 2023, then soared by 168.44% to $108.2 million in 2024, then soared by 83.57% to $198.5 million in 2025.
  • Business Quant data shows Non-cash Items for CGON at $198.5 million in Q4 2025, $190.7 million in Q3 2025, and $106.8 million in Q2 2025.